Matayoshi Takemitsu, Omi Tokuya, Sakai Noriyasu, Kawana Seiji
Department of Dermatology, Nippon Medical School, Tokyo, Japan.
J Nippon Med Sch. 2013;80(4):268-78. doi: 10.1272/jnms.80.268.
A correlation between decreased blood coagulation factor XIII activity and the severity of organ disorders in pediatric Henoch-Schönlein purpura (HSP) has been demonstrated, but possible correlations in adult HSP have not been thoroughly investigated.
To investigate the association between factor XIII activity with varying clinical severities of HSP and the severity of organ disorders and to examine the efficacy of factor XIII substitution therapy.
The distribution of purpura and the severities of joint, abdominal, and renal symptoms were scored in 44 adults with HSP. Plasma factor XIII activity was measured with the latex agglutination immunoturbidity method.
Reduced factor XIII activities were correlated with clinical severity scores (the total of all scores), organ disorder severity scores (the total score excluding the purpura score), joint symptom scores, and abdominal symptom scores but not with renal disorder scores. Factor XIII activities were increased in patients during posttreatment remission. Factor XIII substitution therapy was performed in 7 patients with severe organ disorders. Consequently, joint and abdominal symptoms markedly improved, but renal symptoms did not.
Measurement of plasma factor XIII activity in adult HSP is clinically useful because it indicates disease severity and the severity of digestive tract and joint disorders. Factor XIII substitution therapy is effective for joint and abdominal symptoms but not for renal symptoms. Further investigation of the effect of this treatment on renal symptoms is necessary.
已有研究表明小儿过敏性紫癜(HSP)患者血液凝固因子 XIII 活性降低与器官功能障碍的严重程度相关,但成人 HSP 患者中可能存在的相关性尚未得到充分研究。
探讨因子 XIII 活性与 HSP 不同临床严重程度及器官功能障碍严重程度之间的关联,并检验因子 XIII 替代疗法的疗效。
对 44 例成人 HSP 患者的紫癜分布情况以及关节、腹部和肾脏症状的严重程度进行评分。采用乳胶凝集免疫比浊法测定血浆因子 XIII 活性。
因子 XIII 活性降低与临床严重程度评分(所有评分的总和)、器官功能障碍严重程度评分(不包括紫癜评分的总分)、关节症状评分和腹部症状评分相关,但与肾脏功能障碍评分无关。患者在治疗后缓解期因子 XIII 活性升高。对 7 例严重器官功能障碍患者进行了因子 XIII 替代治疗。结果,关节和腹部症状明显改善,但肾脏症状未改善。
测定成人 HSP 患者血浆因子 XIII 活性在临床上具有重要意义,因为它可提示疾病严重程度以及消化道和关节功能障碍的严重程度。因子 XIII 替代疗法对关节和腹部症状有效,但对肾脏症状无效。有必要进一步研究该治疗对肾脏症状的影响。